Anti-F9/F10 (Emicizumab), Humanized Antibody

Anti-F9/F10 (Emicizumab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a bispecific humanized monoclonal antibody that specifically binds to both Factor IXa and Factor X. The antibody mimics the function of activated Factor VIII that is missing in hemophilic patients. Under normal conditions, the presence of thrombin or other coagulation factors causes dissociation of Factor VIII from vWF and enables the formation of activated Factor VIIIa. Activated Factor VIIIa then binds to activated Factor IXa on the phospholipid surface of platelet cells. This complex formation favors the binding of Factor IXa to Factor X and its subsequent conversion to Factor Xa, which later promotes the coagulation process. Hemophilic patients are deficient in Factor VIII/VIIIa and hence have a dysfunctional process of coagulation. The monoclonal antibody mimics the missing activated Factor VIIIa without the need for thrombin or other coagulation agents, binds to both Factor IXa and Factor X, thus promoting activation of Factor Xa and restoring the coagulation process. The original monoclonal antibody is approved by the FDA to treat patients with hemophilia A

Immunogen Sequence:Human Factor 9/Factor 10

Target Alternative Name:FIX, P19, PTC, HEMB, THPH8, F9 p22, F9, FX, FXA, F10

Species Reactivities:Human

Tag Line:The biosimilar is a bispecific humanized monoclonal antibody that mimics the function of activated Factor VIIIa. It bridges Factor IXa and Factor X and activates Factor Xa. The original monoclonal antibody helps restore hemostasis in hemophilic patients

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.